Things are looking up for the U.S. orthopedics market, as preliminary results for Biomet Inc.‘s 2nd quarter suggest strong growth in domestic knee and hip devices sales.
Privately held Biomet, considered something of a bellwether for the U.S. orthopedics market, touted 6% year-over-year growth in knees and 8% in hips.
Cooper Cos. (NYSE:COO) today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision’s Avaira Toric two-week silicone hydrogel contact lenses for astigmatism.
CooperVision will re-launch Avaira Toric with shipments available for select distribution beginning in early May 2012.
Siemens AG (NYSE:SI) may cut as many as 2,000 positions from its diagnostics and radiation treatment divisions, shifting its focus to lower-cost countries and reducing costs.
The European giant’s diagnostics arm, responsible for nearly one-third of sales in FY 2011, has lagged in the last two years, despite the $13 billion spent giving it an overhaul.
Sweden-based Getinge Group announced a definitive agreement to acquire soft tissue reinforcement technology developer Atrium Medical for $680 million.
Atrium will operate as an independent, self-contained unit of Getinge subsidiary Maquet Cardiovascular and will continue to be led by current Atrium president, Trevor Carlton, according to a press release.
Medical device maker DJO Global, Inc. announced that its executive vice president of U.S. commercial operations, Andrew Holman, will leave the company “to pursue other opportunities.”
Newly minted DJO president & CEO Mike Mogul will assume responsibility for the San Diego, Calif.-based company’s U.S. commercial activities.
Elekta AB (publ) (STO:EKTAB) today announced it has successfully
completed its acquisition of Nucletron, the world leader in
brachytherapy treatment planning and delivery. Through the combination
Elekta will offer a complete range of radiotherapy planning and delivery
technologies. As the market leader in Europe and with strong positions
in North America and Asia, Elekta will enhance the combined ability to
meet the clinical needs of cancer patients and health care providers
throughout the world.
“Now we have successfully completed the acquisition and we are very
enthusiastic about building a broader, stronger and highly complementary
range of cutting-edge cancer care solutions”